SequelSEC

HALOZYME THERAPEUTICS, INC. HALO

Biological Products, (No Diagnostic Substances) · CIK 0001159036 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$1.66B
Fiscal year ended 2026-06-30
Operating income
$597.20M
Fiscal year ended 2026-06-30
Free cash flow
$806.22M
Fiscal year ended 2026-06-30

HALOZYME THERAPEUTICS, INC. (HALO) reported revenue of $1.66B and net income of $413.60M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from HALOZYME THERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

HALOZYME THERAPEUTICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$1.66B
Cost of revenue$292.42M
Gross profit$1.37B
Operating income$597.20M
Net income$413.60M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income$583.34M
Income tax expense$169.74M
Diluted EPSUnavailable
Selling, general & administrative$238.00M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

HALOZYME THERAPEUTICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$163.14M
Total assets$2.58B
Current assets$933.02M
Total liabilities$2.43B
Current liabilities$344.44M
Total equity incl. NCI$143.54M
Temporary (mezzanine) equityUnavailable
Inventory$137.14M
Accounts receivable$453.33M
Goodwill$581.73M
Long-term debt$1.94B
Accounts payable$23.61M

Cash flow

HALOZYME THERAPEUTICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$818.60M
Capital expenditures$12.37M
Investing cash flow-$605.72M
Financing cash flow-$110.75M
Net change in cash$102.12M
Stock-based compensation$63.07M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$14.72M

Derived

HALOZYME THERAPEUTICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$806.22M
Gross margin82.4%
Operating margin35.9%
FCF margin48.5%
SBC / revenue3.8%
Current ratio2.71x
Revenue YoY growth41.2%
Net margin24.9%
R&D / revenueUnavailable
CapEx / revenue0.7%
Long-term debt / equity13.50x
Effective tax rate29.1%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HALO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.